

# Amendment Tool

v1.6 06 December 2021

For office use

QC: No

## Section 1: Project information

Short project title*:	PRINCIPLE			
IRAS project ID* (or REC reference if no IRAS project ID is available):	281958			
Sponsor amendment reference number*:	Substantial Amendment 21			
Sponsor amendment date* (enter as DD/MM/YY):	14 January 2022			
Briefly summarise in lay language the main changes proposed in this amendment. Explain the purpose of the changes and their significance for the study. If the amendment significantly alters the research design or methodology, or could otherwise affect the scientific value of the study, supporting scientific information should be given (or enclosed separately). Indicate whether or not additional scientific critique has been obtained (note: this field will adapt to the amount of text entered)*:	1) Protocol updated to include collection of COVID-19 vaccination status including number of vaccinations received. Study end date extended until Sep 2023. Public Health England name change to UK Health Security Agency 2). Addition of a letter template for participants including instructions on how to return their unused medication. 3) Favipiravir dose regimen and tablet strength amended for second batch of IMP, provided free of charge by IPS Pharma from new Manufacturer (Cellvera) with new IB 4) Change of TSC chair and new member, and replacement DMSC member 5) Updated PN in line with CAG approval conditions			
Project type (select):	<b>Specific study</b>			
	Research tissue bank			
	Research database			
Has the study been reviewed by a UKECA-recognised Research Ethics Committee (REC) prior to this amendment?:	<b>Yes</b>		No	
What type of UKECA-recognised Research Ethics Committee (REC) review is applicable? (select):	<b>NHS/HSC REC</b>			
	Ministry of Defence (MoDREC)			
Is all or part of this amendment being resubmitted to the Research Ethics Committee (REC) as a <b>modified amendment</b> (i.e. a substantial amendment previously given an unfavourable opinion)?	Yes		<b>No</b>	
Where is the NHS/HSC Research Ethics Committee (REC) that reviewed the study based?:	England	Wales	Scotland	Northern Ireland
	<b>Yes</b>	No	No	No
Was the study a clinical trial of an investigational medicinal product (CTIMP) OR does the amendment make it one?:	<b>Yes</b>		No	
EudraCT number*:	2020-001209-22			
Was this clinical trial of an investigational medicinal product (CTIMP) processed under the CTIMP combined review service (formerly known as the Combined Ways of Working (CWOW) pilot)?:	<b>Yes</b>		No	
Did the study receive Pharmacy Assurance?:	Yes		<b>No</b>	
Was the study a clinical investigation or other study of a medical device OR does the amendment make it one?:	Yes		<b>No</b>	
Did the study involve the administration of radioactive substances, therefore requiring ARSAC review, OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve the use of research exposures to ionising radiation (not involving the administration of radioactive substances) OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve adults lacking capacity OR does the amendment introduce this?:	<b>Yes</b>		No	
Did the study involve access to confidential patient information outside the direct care team without consent OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve prisoners or young offenders who are in custody or supervised by the probation service OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve children OR does the amendment introduce this?:	Yes		<b>No</b>	
Did the study involve NHS/HSC organisations prior to this amendment?:	<b>Yes</b>		No	
Did the study involve non-NHS/HSC organisations OR does the amendment introduce them?:	Yes		<b>No</b>	
	England	Wales	Scotland	Northern Ireland
Lead nation for the study:	<b>Yes</b>	No	No	No
Which nations had participating NHS/HSC organisations prior to this amendment?	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>
Which nations will have participating NHS/HSC organisations after this amendment?	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>	<b>Yes</b>

## Section 2: Summary of change(s)

What do you want to update?:	Chief Investigator
	Sponsor Group
	Administrative
Project information	

**Please note:** Each change being made as part of the amendment must be entered separately. For example, if an amendment to a clinical trial of an investigational medicinal product (CTIMP) involves an update to the Investigator's Brochure (IB), affecting the Reference Safety Information (RSI) and so the information documents to be given to participants, these should be entered into the Amendment Tool as three separate changes. A list of all possible changes is available on the "Glossary of Amendment Options" tab. To add another change, click the "Add another change" box.

Change 1				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Protocol - Non-substantial changes (e.g. not affecting safety or the scientific value of the trial)			
Further information (free text - note that this field will adapt to the amount of text entered):	COVID-19 vaccination status including number of vaccinations received added. Study end date updated to September 2023 (separate change listed below). All reference to Public Health England amended to UK Health Security Agency in line with new name, updated in the protocol and PIS.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 2				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other significant change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	Participants who withdraw from IMP are asked to return any unused medication to the trial team. A new letter template has been created and will be enclosed when sending return envelopes to participants detailing how to return their medication.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 3				
Area of change (select)*:	CTIMP IMP			
Specific change (select - only available when area of change is selected first)*:	Other - Please specify in the free text below			
Further information (free text - note that this field will adapt to the amount of text entered):	The strength of the tablets will change from 200mg to 400mg. The dosage will change to 9 tablets on day one (5 tablets AM, 4 tablets PM), followed by 2 tablets twice a day for days 2-5. This will result in a reduction to the number of total tablets to be taken by participants on this arm of the trial to 25 (previously 50 tablets total), reducing the tablet burden on the participant. Updated Investigator Brochure and IMP label template provided. Favipiravir to be provided free of charge by IPS Pharma in exchange for data related to this arm of the trial.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
Remove all changes below				

Change 4	
Area of change (select)*:	Administrative details for the project

Specific change (select - only available when area of change is selected first)*:	Other administrative change - Please specify in the free text below			
Further information (free text - note that this field will adapt to the amount of text entered):	Change of Trial Steering Committee (TSC) chair and new committee member listed, due to conflict of interest with PANORAMIC trial. Replacement of Data & Safety Monitoring Committee (DMSC) member due to conflict of interest with PANORAMIC trial. Update to privacy notice following recommendations from CAG to satisfy conditions of CAG approval (changes already agreed with CAG)			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
			Remove all changes below	

Change 5				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	Other minor change to study documents (e.g. information sheets, consent forms, questionnaires, letters) that can be implemented within existing resource in place at participating organisations - Please specify in the free text below			
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	Patient facing documents (PIS Appendices and Favipiravir Participant Card) have been updated with the IMP administration changes described in 'Change 3'.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
			Remove all changes below	

Change 6				
Area of change (select)*:	Study Design			
Specific change (select - only available when area of change is selected first)*:	Extension to study duration that will not have any additional resource implications for participating organisations - Please specify in the free text below			
Further information In particular, please describe why this change can be implemented within the existing resource in place at the participating organisations (free text - note that this field will adapt to the amount of text entered)*	The study end date has been extended to September 2023 to allow sufficient time to complete the study, where optional twelve month follow-up is carried out for some participants, after the initial 28 day participation in the trial. The follow up is completed by the study team and therefore does not require additional resources from sites.			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
			Remove all changes below	

Change 7				
Area of change (select)*:	Study Documents			
Specific change (select - only available when area of change is selected first)*:	IB, SmPC - Non-substantial changes (e.g. that do not affect risk/benefit assessment)			
Further information (free text - note that this field will adapt to the amount of text entered):	Updated Favipiravir Investigator Brochure, v3.0 dated 03-Feb-22. Favipiravir manufacturer changed from Fujifilm Toyama Chemical Company Ltd to Cellvera Asia Ltd. Protocol and MHRA CTA form updated			
Applicability:	England	Wales	Scotland	Northern Ireland
Where are the participating NHS/HSC organisations located that will be affected by this change?*	Yes	Yes	Yes	Yes
Will all participating NHS/HSC organisations be affected by this change, or only some? ( <b>please note</b> that this answer may affect the categorisation for the change):	All		Some	
			Add another change	

### Section 3: Declaration(s) and lock for submission

#### Declaration by the Sponsor or authorised delegate

- I confirm that the Sponsor takes responsibility for the completed amendment tool
- I confirm that I have been formally authorised by the Sponsor to complete the amendment tool on their behalf

Applicant identification:	<b>Sponsor</b>
	Legal representative of the sponsor Person or organisation authorised by the sponsor
Organisation:	University of Oxford
Name [first name and surname]*:	Elaine Chick
Address:	Boundary Brook House, Oxford
Telephone number:	
Fax number:	
Purchase Order (PO) number for MHRA invoicing:	TBC
Email address*:	jared.robinson@phc.ox.ac.uk; ctrg@admin.ox.ac.uk

#### Lock for submission

**Please note:** This button will only become available when all mandatory (\*) fields have been completed. When the button is available, clicking it will generate a locked PDF copy of the completed amendment tool which must be included in the amendment submission. Please ensure that the amendment tool is completed correctly before locking it for submission.

**Lock for submission**

After locking the tool, amendments to trials processed under the combined review service should be made using the new part of IRAS. Further information can be found on the "Submission Guidance" tab.

### Section 4: Review bodies for the amendment

**Please note:** This section is for **information only**. Details in this section will complete automatically based on the options selected in Sections 1 and 2.

	Review bodies														Category:				
	UK wide:					England and Wales:				Scotland:			Northern Ireland:						
	REC	Competent Authority MHRA - Medicines	Competent Authority MHRA - Devices	ARSAC	Radiation Assurance	UKSW Governance	REC (MCA)	CAG	HMPPS	HRA and HCRW Approval	REC (AWIA)	PBPP	SPS (RAEC)	National coordinating function		HSC REC	HSC Data Guardians	Prisons	National coordinating function
Change 1:	N	N				(Y)				(Y)				(Y)				(Y)	A
Change 2:	Y	N				Y				Y				Y				Y	C
Change 3:	Y	Y				Y				Y				Y				Y	A
Change 4:	N	N				Y				(Y)				(Y)				(Y)	C
Change 5:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 6:	N	N				(Y)				(Y)				(Y)				(Y)	C
Change 7:	N	N				(Y)				(Y)				(Y)				(Y)	C
Overall reviews for the amendment:																			
Full review:	Y	Y				Y				Y				Y				Y	
Notification only:	N	N				N				N				N				N	
Overall amendment type:	Substantial for review																		
Overall Category:	A																		
For national coordinating function office use:																			

Update HARP:

This amendment may involve an update to contact details, project end date, or other project details. Ensure that HARP is updated with the current details. If this is the only change, no further study-wide review is required.